Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
NCT02878603
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
104
Enrollment
INDUSTRY
Sponsor class
Conditions
Acquired Thrombotic Thrombocytopenic Purpura
Interventions
BIOLOGICAL:
Caplacizumab
OTHER:
Standard of Care
Sponsor
Sanofi